Subscribe
210126-N-NH199-1017
SAN DIEGO (Jan 26, 2020) Lt. Cmdr. Raben Talvo, Naval Medical Center San Diego's (NMCSD) Office of Clinical Quality department head (left), and Hospital Corpsman 1st Class Angela Ramirez (right) administer the hospital’s first monoclonal antibody (mAb) treatment to a COVID-19-positive patient Jan. 26. Bamlanivimab, the mAb treatment, is administered under emergency use authorization (EUA) guidance from the U.S. Food and Drug Administration (FDA) to treat mild to moderate COVID-19 symptoms in some adult and pediatric patients who are at high risk for progressing to severe COVID-19 symptoms. NMCSD's mission is to prepare service members to deploy in support of operational forces, deliver high quality healthcare services, and shape the future of military medicine through education, training, and research. NMCSD employs more than 6,000 active duty military personnel, civilians, and contractors in Southern California to provide patients withworld-class care anytime, anywhere. (U.S. Navy photo by Mass Communication Specialist 3rd Class Harley K. Sarmiento)
| Date Taken: | 01.26.2021 |
| Date Posted: | 01.29.2021 16:29 |
| Photo ID: | 6501446 |
| VIRIN: | 210126-N-NH199-1017 |
| Resolution: | 4085x2918 |
| Size: | 1.03 MB |
| Location: | SAN DIEGO, CALIFORNIA, US |
| Web Views: | 83 |
| Downloads: | 7 |
This work, NMCSD Administers First Monoclonal Antibody (mAb) Treatment [Image 4 of 4], by PO3 Harley Sarmiento, identified by DVIDS, must comply with the restrictions shown on https://www.dvidshub.net/about/copyright.
NMCSD Administers Hospital’s First mAb Treatment to COVID-19 Patient
No keywords found.
